Videos

Ghaith Noaiseh, MD, explains how dazodalibep’s CD40 ligand blockade works and reviews dryness and safety data from OASIZ-301 at ACR 2026.

Ghaith Noaiseh, MD, discusses phase 3 OASIZ-301 results showing dazodalibep reduced systemic disease activity in Sjögren’s disease at ACR 2026.

Using the ESSDAI as a review-of-systems guide and tracking immunologic markers can help rheumatologists prepare for targeted Sjögren’s therapies.

FcRn blockade, CD40 ligand inhibition, dual BAFF and APRIL blockade, and repurposed DMARDs are expanding treatment options in Sjögren’s disease.

Payer reliance on the ESSDAI and widespread underdiagnosis may limit access to new Sjögren’s disease therapies without better screening in practice.

Ianalumab may best suit Sjögren’s patients with systemic, B-cell-driven disease, and phase 3 safety data have so far tracked closely with placebo.

Ianalumab met its primary end point in 2 phase 3 Sjögren’s disease trials, though the modest effect size shapes which patients may benefit most.

Disease heterogeneity, irreversible glandular damage, and imperfect outcome measures help explain why Sjögren’s disease trials repeatedly fell short.

John Stone, MD, MPH, discusses INDIGO open-label extension data showing durable flare control with obexelimab in IgG4-related disease at ACR 2026.

ACR 2026 real-world data associate upadacitinib with greater joint count reductions than IL-17 inhibitors after prior TNF inhibitor use.

PERIS interim data show improvements in joint, entheseal, and skin outcomes with risankizumab in patients with PsA.

ACR 2026 data link circulating protein signatures to PsA disease activity and treatment response with deucravacitinib.

Furie explains how nipocalimab clears IgG autoantibodies and why the JASMINE subgroups could shape phase 3.

Philip Mease, MD, discusses BE BOLD head-to-head results plus new indirect and real-world comparisons shaping PsA treatment choices at ACR 2026.

Phase 3 data presented at ACR Convergence 2026 show up to 28.7% weight loss with the triple agonist, alongside sustained knee pain relief.

SABLE registry data show numerically lower 5-year mortality with belimumab vs conventional immunosuppressants in patients with SLE.

Philip Mease, MD, discusses TOGETHER-PsA data on ixekizumab plus tirzepatide and why addressing obesity is becoming central to PsA care.

Philip Mease, MD, discusses pooled INSPIRE 1 and 2 data supporting tildrakizumab’s approval in psoriatic arthritis, presented at ACR 2026.

Protein intake, pacing weight loss safely, and remembering that one patient in front of you has one life to live round out a rheumatologist's closing clinical pearls.

A clinician's dosing and nutrition guidance meets a patient's hard-won advice for anyone entering combination therapy: manage expectations, stay engaged with your doctor, and be willing to keep exploring.

Dr. Bakewell and Dr. Perkins highlight new ongoing studies in PsA care and a shrinking medication list with combination approach.

Beyond joint counts and skin scores, the panel examines how combination therapy touched a veteran's mental health, and where cardiac, cognitive, and other comorbidity research is heading next.

Casual observations about benefits of incretin therapy in patients with psoriatic diseases lead to combination therapy approach and TOGETHER-PsA trial.

Obesity affects the majority of patients with psoriatic arthritis and can blunt even the best available biologics, raising the question of weight-based dosing and new treatment tools.

Eight medications, one persistent rash, and a run of trial and error trace the real-world difficulty of matching a psoriatic arthritis patient to the drug that finally works.

Kameillia Welch gives a deeply personal account of how one patient finally reached a diagnosis after years of unexplained pain.

A veteran's decade-long path through psoriatic arthritis and obesity opens the program, setting up a wide-ranging look at diagnosis, treatment, and the disease's true prevalence.

Kate Harnden, MBChB, discusses new study that identifies factors tied to disease persistence in patients with immune checkpoint inhibitor-induced arthritis and arthralgia.

Shah shares conversations from a recent clinical forum on best practices and collaboration for interstitial lung disease management.

KEEPsAKE 1 long-term data confirm sustained MDA responses, structural protection in nearly 9 in 10 patients, and a cardiovascular safety signal that may favor IL-23 inhibition over JAK inhibitors.